{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:47:05Z","timestamp":1789501625413,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011015","name":"ISTM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In 2013, the World Health Organization (WHO) revised their position on yellow fever vaccination, in which revaccination every 10 years was no longer required, and that a single-dose provided life-long protection. However, research data on the immunogenicity of YF vaccine in people aged 60\u00a0years and over are scarce. Indeed, immunosenescence may result in lower virus neutralizing antibody titers after primary vaccination and a more rapid waning immunity. Therefore, we tested the hypothesis that older travelers, vaccinated at 60\u00a0years or older are more likely to become seronegative in comparison to young adults 10 years after primary YF vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a 10-year follow-up study of an earlier prospective controlled cohort study. In the original trial, the neutralizing antibody response was measured in older travelers (aged 60\u201381\u00a0years, N\u2009=\u200928) and young adults (aged 18\u201328\u00a0years, N\u2009=\u200930) up to 28\u00a0days after a primary yellow fever vaccination. Ten years later, we collected serum samples of 22\/28 (78%) elderly (71\u201385\u00a0years) and 14\/30 (47%) controls (29\u201340\u00a0years), and determined their neutralizing antibody titers by plaque reduction neutralization test (PRNT80). Seropositivity was defined as plaque formation reduction of 80% at a serum dilution of 10 or more (PRNT80\u2009\u2265\u200910).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All participants (36\/36) were still seropositive 10 years after primary vaccination. The geometric mean concentrations were not statistically different between the older and younger participants (6.7\u00a0IU\/mL vs. 8.6\u00a0IU\/mL, P\u2009=\u20090.5).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>All older travelers were seropositive, 10 years after a primary YF vaccination at the age of \u226560\u00a0years. These data suggest that in older travelers a single vaccination is sufficient to convey long-lasting immunity for at least 10\u00a0years, and is in support the position of the WHO on a single-dose yellow fever vaccination.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taab126","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T19:11:18Z","timestamp":1628449878000},"source":"Crossref","is-referenced-by-count":20,"title":["Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60\u00a0years or older: A 10-year follow-up study"],"prefix":"10.1093","volume":"28","author":[{"given":"Mareen D","family":"Rosenstein","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00ebtte W","family":"de Visser","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-9782","authenticated-orcid":false,"given":"Leo G","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1397-0992","authenticated-orcid":false,"given":"Anna H E","family":"Roukens","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"2021122911111775200_ref1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J Clin Virol"},{"key":"2021122911111775200_ref2","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1016\/j.vaccine.2017.03.032","article-title":"Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease","volume":"35","author":"Barrett","year":"2017","journal-title":"Vaccine"},{"key":"2021122911111775200_ref3","first-page":"201","article-title":"April 2013 - conclusions and recommendations","volume":"88","author":"Meeting of the Strategic Advisory Group of Experts on immunization","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"key":"2021122911111775200_ref4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vaccine.2014.05.040","article-title":"Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013--recommendations","volume":"33","author":"WHO","year":"2015","journal-title":"Vaccine"},{"key":"2021122911111775200_ref5","volume-title":"Amendment to International Health Regulations (2005), Annex 7 (yellow fever)","year":"2016"},{"key":"2021122911111775200_ref6","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3201\/eid2508.181432","article-title":"17DD yellow fever revaccination and heightened long-term immunity in populations of disease-endemic areas","volume":"25","author":"Campi-Azevedo","year":"2019","journal-title":"Brazil Emerg Infect Dis"},{"key":"2021122911111775200_ref7","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1016\/j.vaccine.2014.07.021","article-title":"Duration of post-vaccination immunity against yellow fever in adults","volume":"32","author":"Collaborative group for studies on yellow fever v","year":"2014","journal-title":"Vaccine"},{"key":"2021122911111775200_ref8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/21645515.2015.1082693","article-title":"Booster dose after 10 years is recommended following 17DD-YF primary vaccination","volume":"12","author":"Campi-Azevedo","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2021122911111775200_ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmaid.2016.12.003","article-title":"Yellow fever vaccination - Once in a lifetime?","volume":"15","author":"Grobusch","year":"2017","journal-title":"Travel Med Infect Dis"},{"key":"2021122911111775200_ref10","volume-title":"An Aging World: 2015","author":"Wan He","year":"2016"},{"key":"2021122911111775200_ref11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum Vaccin"},{"key":"2021122911111775200_ref12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s13149-011-0135-7","article-title":"Long term persistence of yellow fever neutralising antibodies in elderly persons","volume":"104","author":"Coulange Bodilis","year":"2011","journal-title":"Bull Soc Pathol Exot"},{"key":"2021122911111775200_ref13","doi-asserted-by":"crossref","DOI":"10.1590\/s1678-9946201759002","article-title":"Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults","volume":"59","author":"Miyaji","year":"2017","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"2021122911111775200_ref14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027753","article-title":"Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study","volume":"6","author":"Roukens","year":"2011","journal-title":"PLoS One"},{"key":"2021122911111775200_ref15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJMoa1710430","article-title":"Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report","volume":"381","author":"Casey","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122911111775200_ref16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF03324904","article-title":"Immunosenescence and vaccine failure in the elderly","volume":"21","author":"Grubeck-Loebenstein","year":"2009","journal-title":"Aging Clin Exp Res"},{"key":"2021122911111775200_ref17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun Ageing"},{"key":"2021122911111775200_ref18","first-page":"113","article-title":"A simple micro-culture method for the study of group B arboviruses","volume":"40","author":"De Madrid","year":"1969","journal-title":"Bull World Health Organ"},{"key":"2021122911111775200_ref19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/M18-1529","article-title":"Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled","volume":"169","author":"Roukens","year":"2018","journal-title":"Noninferiority Trial Ann Intern Med"},{"key":"2021122911111775200_ref20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/am.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microbiol"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taab126\/40214834\/taab126.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/28\/8\/taab126\/41959273\/taab126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/28\/8\/taab126\/41959273\/taab126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T12:44:27Z","timestamp":1640781867000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taab126\/6353012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,16]]},"published-print":{"date-parts":[[2021,12,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taab126","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12]]},"published":{"date-parts":[[2021,8,16]]},"article-number":"taab126"}}